June 9, 2016 – Today, at the largest global biotech forum, BIO International Convention, that took place in San Francisco, USA, SatRx LLC, a ChemRar company specializing in research and development in the fields of diabetes and cardiometabolic disorders, announced the first market registration of its innovative drug for the treatment of Type 2 diabetes, SatRx® (gosogliptin), in Russia.
Saint-Petersburg, June 21, 2013: Today during the Saint-Petersburg International Economic Forum-2013 Dompé, one of Italy’s leading biopharmaceutical companies, and SatRx, a Russian biotechnology company specialised on the development of innovative medicines used in solid organ transplantation and for the treatment of metabolic diseases, such as diabetes and obesity, announced that they have signed a collaboration agreement for the clinical development of Reparixin, an innovative drug discovered by Dompé, to improve efficacy of liver transplantation. The alliance between the companies focuses on Phase II-III clinical trials which are the final stages of clinical development prior to drug marketing.
Saint-Petersburg, June 22, 2012: Today during the Saint-Petersburg International Economic Forum-2012 Pfizer Inc. and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center (ChemRar) announced an agreement under which Pfizer grants the ChemRar group company SatRx an exclusive rights to PF-00734200, a DPP -IVi compound. The DPP-IVi compound is being developed for treatment of Type 2 Diabetes, one of the most burdensome chronic non-communicable diseases, which is fast gaining epidemic proportions throughout the world.